These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 37609899)

  • 21. Impact of Hepatic CYP3A4 Ontogeny Functions on Drug-Drug Interaction Risk in Pediatric Physiologically-Based Pharmacokinetic/Pharmacodynamic Modeling: Critical Literature Review and Ivabradine Case Study.
    Lang J; Vincent L; Chenel M; Ogungbenro K; Galetin A
    Clin Pharmacol Ther; 2021 Jun; 109(6):1618-1630. PubMed ID: 33283268
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Association between clinically relevant toxicities of pazopanib and sunitinib and the use of weak CYP3A4 and P-gp inhibitors.
    Azam C; Claraz P; Chevreau C; Vinson C; Cottura E; Mourey L; Pouessel D; Guibaud S; Pollet O; Le Goff M; Bardies C; Pelagatti V; Canonge JM; Puisset F
    Eur J Clin Pharmacol; 2020 Apr; 76(4):579-587. PubMed ID: 31932871
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical implications of trials investigating drug-drug interactions between cannabidiol and enzyme inducers or inhibitors or common antiseizure drugs.
    Patsalos PN; Szaflarski JP; Gidal B; VanLandingham K; Critchley D; Morrison G
    Epilepsia; 2020 Sep; 61(9):1854-1868. PubMed ID: 32918835
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Application of a "Fit for Purpose" PBPK Model to Investigate the CYP3A4 Induction Potential of Enzalutamide.
    Narayanan R; Hoffmann M; Kumar G; Surapaneni S
    Drug Metab Lett; 2016; 10(3):172-179. PubMed ID: 27604990
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Physiologically based pharmacokinetic modeling to assess metabolic drug-drug interaction risks and inform the drug label for fedratinib.
    Wu F; Krishna G; Surapaneni S
    Cancer Chemother Pharmacol; 2020 Oct; 86(4):461-473. PubMed ID: 32886148
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prediction of the drug-drug interaction potential of the α1-acid glycoprotein bound, CYP3A4/CYP2C9 metabolized oncology drug, erdafitinib.
    De Zwart L; Snoeys J; Jacobs F; Li LY; Poggesi I; Verboven P; Goris I; Scheers E; Wynant I; Monshouwer M; Mamidi RNVS
    CPT Pharmacometrics Syst Pharmacol; 2021 Sep; 10(9):1107-1118. PubMed ID: 34273250
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Use of a Physiologically Based Pharmacokinetic Model for Quantitative Prediction of Drug-Drug Interactions via CYP3A4 and Estimation of the Intestinal Availability of CYP3A4 Substrates.
    Mano Y; Sugiyama Y; Ito K
    J Pharm Sci; 2015 Sep; 104(9):3183-93. PubMed ID: 26045365
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Physiologically-based pharmacokinetic modeling of quinidine to establish a CYP3A4, P-gp, and CYP2D6 drug-drug-gene interaction network.
    Feick D; Rüdesheim S; Marok FZ; Selzer D; Loer HLH; Teutonico D; Frechen S; van der Lee M; Moes DJAR; Swen JJ; Schwab M; Lehr T
    CPT Pharmacometrics Syst Pharmacol; 2023 Aug; 12(8):1143-1156. PubMed ID: 37165978
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Physiologically based pharmacokinetic modelling to predict the clinical effect of CYP3A inhibitors/inducers on esaxerenone pharmacokinetics in healthy subjects and subjects with hepatic impairment.
    Watanabe A; Ishizuka T; Yamada M; Igawa Y; Shimizu T; Ishizuka H
    Eur J Clin Pharmacol; 2022 Jan; 78(1):65-73. PubMed ID: 34415382
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Drug-drug interaction prediction of ziritaxestat using a physiologically based enzyme and transporter pharmacokinetic network interaction model.
    Perrier J; Gualano V; Helmer E; Namour F; Lukacova V; Taneja A
    Clin Transl Sci; 2023 Nov; 16(11):2222-2235. PubMed ID: 37667518
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Tipifarnib physiologically-based pharmacokinetic modeling to assess drug-drug interaction, organ impairment, and biopharmaceutics in healthy subjects and cancer patients.
    Okudaira N; Burt H; Mitra A
    CPT Pharmacometrics Syst Pharmacol; 2024 Aug; 13(8):1366-1379. PubMed ID: 38807307
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Application of Physiologically Based Pharmacokinetic Modeling to the Understanding of Bosutinib Pharmacokinetics: Prediction of Drug-Drug and Drug-Disease Interactions.
    Ono C; Hsyu PH; Abbas R; Loi CM; Yamazaki S
    Drug Metab Dispos; 2017 Apr; 45(4):390-398. PubMed ID: 28167538
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prediction of drug-drug interactions between roflumilast and CYP3A4/1A2 perpetrators using a physiologically-based pharmacokinetic (PBPK) approach.
    Jia G; Ren C; Wang H; Fan C
    BMC Pharmacol Toxicol; 2024 Jan; 25(1):4. PubMed ID: 38167223
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Simultaneously predict pharmacokinetic interaction of rifampicin with oral versus intravenous substrates of cytochrome P450 3A/P‑glycoprotein to healthy human using a semi-physiologically based pharmacokinetic model involving both enzyme and transporter turnover.
    Qian CQ; Zhao KJ; Chen Y; Liu L; Liu XD
    Eur J Pharm Sci; 2019 Jun; 134():194-204. PubMed ID: 31047967
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A Physiologically Based Pharmacokinetic Model of Voriconazole Integrating Time-Dependent Inhibition of CYP3A4, Genetic Polymorphisms of CYP2C19 and Predictions of Drug-Drug Interactions.
    Li X; Frechen S; Moj D; Lehr T; Taubert M; Hsin CH; Mikus G; Neuvonen PJ; Olkkola KT; Saari TI; Fuhr U
    Clin Pharmacokinet; 2020 Jun; 59(6):781-808. PubMed ID: 31853755
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Simultaneous Physiologically Based Pharmacokinetic (PBPK) Modeling of Parent and Active Metabolites to Investigate Complex CYP3A4 Drug-Drug Interaction Potential: A Case Example of Midostaurin.
    Gu H; Dutreix C; Rebello S; Ouatas T; Wang L; Chun DY; Einolf HJ; He H
    Drug Metab Dispos; 2018 Feb; 46(2):109-121. PubMed ID: 29117990
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comprehensive PBPK model to predict drug interaction potential of Zanubrutinib as a victim or perpetrator.
    Wang K; Yao X; Zhang M; Liu D; Gao Y; Sahasranaman S; Ou YC
    CPT Pharmacometrics Syst Pharmacol; 2021 May; 10(5):441-454. PubMed ID: 33687157
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Ibrutinib Dosing Strategies Based on Interaction Potential of CYP3A4 Perpetrators Using Physiologically Based Pharmacokinetic Modeling.
    de Zwart L; Snoeys J; De Jong J; Sukbuntherng J; Mannaert E; Monshouwer M
    Clin Pharmacol Ther; 2016 Nov; 100(5):548-557. PubMed ID: 27367453
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Impact of posaconazole and diltiazem on pharmacokinetics of encorafenib, a BRAF V600 kinase inhibitor for melanoma and colorectal cancer with BRAF mutations.
    Hahn E; Chavira R; Wollenberg L; Tan W; Reddy MB
    Clin Transl Sci; 2023 Dec; 16(12):2675-2686. PubMed ID: 37837178
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Simultaneous Ivabradine Parent-Metabolite PBPK/PD Modelling Using a Bayesian Estimation Method.
    Lang J; Vincent L; Chenel M; Ogungbenro K; Galetin A
    AAPS J; 2020 Oct; 22(6):129. PubMed ID: 33033962
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.